Pfizer Bullish The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Pfizer's (NYSE:PFE) Staquis (crisaborole) for the treatment of adults and pediatric patients at least two years old with mild or moderate atopic dermatitis with no more than 40% of body surface area affected.
A final decision from the European Commission usually takes ~60 days.
Source seeking alpha
Lovely Fibonacci retrace, will trade the next level/
P/E ratio 13
Average analysts price target $43 | Overweight